TScan Therapeutics, Inc. Share Price
TCRXTScan Therapeutics, Inc. Stock Performance
Open $1.14 | Prev. Close N/A | Circuit Range N/A |
Day Range $1.14 - $1.19 | Year Range N/A | Volume 16,553 |
Average Traded $1.18 |
TScan Therapeutics, Inc. Share Price Chart
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
29-Apr-26 | $1.22 | $1.16 | -8.70% |
28-Apr-26 | $1.27 | $1.26 | -3.07% |
27-Apr-26 | $1.27 | $1.30 | +4.40% |
24-Apr-26 | $1.18 | $1.25 | +3.31% |
23-Apr-26 | $1.27 | $1.21 | -2.81% |
22-Apr-26 | $1.27 | $1.25 | -3.11% |
21-Apr-26 | $1.36 | $1.28 | -10.45% |
FAQs on TScan Therapeutics, Inc. Share Price
Can I buy TScan Therapeutics, Inc. shares in India?
What is the share price of TScan Therapeutics, Inc.?
What is the 5 year returns of TScan Therapeutics, Inc.?
What are the high & low stock price of TScan Therapeutics, Inc. today?
What is the 52-week high and low of TScan Therapeutics, Inc. stock?